Hepatology Elsewhere

Abstract

The recently published BEZURSO trial (Corpechot C, Chazouilleres A, Rousseau A, et al. A placebo‐controlled trial of bezafibrate in primary biliary cholangitis. NEJM 2018;378:2171‐2181.) studied the role of bezafibrate, a peroxisome proliferator‐activated receptor α (PPARα) agonist, in patients with primary biliary cholangitis (PBC) who failed to achieve a biochemical response with ursodeoxycholic acid (UDCA).¹ The BEZURSO trial, a phase 3, double blind, placebo‐controlled trial, randomized patients to receive 24 months of either bezafibrate, 400 mg a day, or placebo. All patients continued UDCA.

This article is protected by copyright. All rights reserved.

http://bit.ly/2TaCyAC